专利检索 ap:("Baxalta Incorporated" OR "Baxalta GmbH") AND inv:"PLAIMAUER, Barbara" 第 1 页

1.

发明授权
DETECTION OF CIRCULATING ADAMTS13-ANTIBODY COMPLEXES 有权
标题翻译：循环ADAMTS13抗体配合物的检测

公开(公告)号：EP2710377B8

公开(公告)日：2015-10-28

申请号：EP12725948.9

申请日：2012-05-18

申请人： Baxalta Incorporated , Baxalta GmbH

发明人： FERRARI, Silvia , GRUBER, Bernadette , PLAIMAUER, Barbara , ROTTENSTEINER, Hanspeter , SCHEIFLINGER, Friedrich

IPC分类号： G01N33/564

CPC分类号： G01N33/564

2.

发明公开
COMPOSITIONS COMPRISING ADAMTS13 FOR USE IN METHODS FOR THE RECANALIZATION OF OCCLUDED BLOOD VESSELS IN AN INFARCTION 审中-公开
标题翻译：包含ADAMTS的组合物13用于在梗塞中再闭塞闭塞的血管的方法

公开(公告)号：EP3302533A1

公开(公告)日：2018-04-11

申请号：EP16729425.5

申请日：2016-05-26

申请人： Baxalta Incorporated , Baxalta GmbH , Katholieke Universiteit Leuven

发明人： PLAIMAUER, Barbara , ROTTENSTEINER, Hanspeter , SCHEIFLINGER, Friedrich , DE MEYER, Simon , DENORME, Frederik

IPC分类号： A61K38/48 , A61P9/10

CPC分类号： A61K38/4886 , A61P9/10 , C12Y304/24087

摘要： Provided herein are methods for recanalization of occluded blood vessels in a subject having an infarction. The method includes a step of administering to the subject a therapeutically effective amount of isolated ADAMTS13 protein at particular dosages and ranges of times after detection of the infarction. As described herein, ADAMTS13 advantageously recanalizes occluded blood vessels and reduces infarction size, even when administered a prolonged period after stable occlusion. Accordingly, such methods and compositions are useful for the treatment of infractions caused by blood vessel occlusion.

3.

发明授权
SUBSTANTIALLY ANIMAL PROTEIN-FREE RECOMBINANT FURIN AND METHODS FOR PRODUCING SAME 有权

公开(公告)号：EP2240578B1

公开(公告)日：2019-03-20

申请号：EP08869658.8

申请日：2008-12-19

申请人： Baxalta GmbH , Baxalta Incorporated

发明人： PLAIMAUER, Barbara , VON FIRCKS, Simone , GRILLBERGER, Leopold , HASSLACHER, Meinhard , GEYER, Roland , MITTERER, Artur , REITER, Manfred

IPC分类号： C12N9/64 , C07K14/755 , C12P21/02

4.

发明公开
SUBCUTANEOUS ADMINISTRATION OF ADAMTS13 审中-公开
标题翻译： SUBKUTANE VERABREICHUNG VON ADAMTS13

公开(公告)号：EP2968483A1

公开(公告)日：2016-01-20

申请号：EP14719469.0

申请日：2014-03-13

申请人： Baxalta Incorporated , Baxalta GmbH

发明人： SCHIVIZ, Alexandra, Nathalie , HOELLRIEGL, Werner , PLAIMAUER, Barbara , ROTTENSTEINER, Hanspeter , MUCHITSCH, Eva-Maria

IPC分类号： A61K38/48 , A61P7/02

CPC分类号： A61K38/4886 , A61K9/0019 , A61K9/19 , C12N9/6489 , C12Y304/24087

摘要： This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.

摘要翻译： 本发明涉及皮下给予ADAMTS13制剂以治疗与ADAMTS13和VWF功能障碍相关的疾病或病症的方法。此外，本文提供了皮下给药的ADAMTS13制剂意想不到的高生物利用度的证据。